First AD

Second AD

Treatment Decision Making in first-line combinations for advanced RCC 

What are the available first-line combination options for advanced RCC?

Please discuss your rationale for choosing between IO+IO and IO+TKI approaches and review these data: Network meta-analysis (NMA) – 

Grunwald, et al. ASCO GU 2024. Abstract 482 –

len + pembro vs other 1L treatments in advanced RCC

How do you approach treatment selection in the frontline setting?

What factors do you consider when choosing treatment?

Which patients do you choose len-pembro versus axi-pembro versus cabo-nivo?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC  

The key opinion leaders explore the various first-line combination treatment options for advanced renal cell carcinoma, including immuno-oncology plus immuno-oncology (IO+IO) and immuno-oncology plus tyrosine kinase inhibitor (IO+TKI) approaches, while also considering the optimal sequencing of treatments to maximize patient benefit. 